Pettinga Financial Advisors LLC Raises Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Pettinga Financial Advisors LLC boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 290.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,875 shares of the exchange traded fund’s stock after purchasing an additional 10,325 shares during the quarter. Pettinga Financial Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,058,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Main Management ETF Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 6.4% during the 2nd quarter. Main Management ETF Advisors LLC now owns 299,700 shares of the exchange traded fund’s stock worth $26,287,000 after acquiring an additional 18,000 shares in the last quarter. Bank of Nova Scotia boosted its position in shares of SPDR S&P Biotech ETF by 2.5% during the 2nd quarter. Bank of Nova Scotia now owns 289,053 shares of the exchange traded fund’s stock worth $25,353,000 after acquiring an additional 6,943 shares in the last quarter. LPL Financial LLC boosted its position in shares of SPDR S&P Biotech ETF by 1.0% during the 2nd quarter. LPL Financial LLC now owns 219,154 shares of the exchange traded fund’s stock worth $19,222,000 after acquiring an additional 2,096 shares in the last quarter. Cumberland Advisors Inc. boosted its position in shares of SPDR S&P Biotech ETF by 2.5% during the 3rd quarter. Cumberland Advisors Inc. now owns 211,059 shares of the exchange traded fund’s stock worth $16,093,000 after acquiring an additional 5,230 shares in the last quarter. Finally, Whittier Trust Co. boosted its position in shares of SPDR S&P Biotech ETF by 3.6% during the 2nd quarter. Whittier Trust Co. now owns 200,588 shares of the exchange traded fund’s stock worth $17,593,000 after acquiring an additional 7,012 shares in the last quarter.

Shares of NYSEARCA:XBI traded down $0.79 on Friday, hitting $78.82. 577,014 shares of the company’s stock were exchanged, compared to its average volume of 4,746,731. The firm’s 50-day moving average is $79.24 and its 200 day moving average is $83.61. SPDR S&P Biotech ETF has a 1-year low of $64.38 and a 1-year high of $93.87.

The firm also recently disclosed a — dividend, which was paid on Wednesday, September 25th. Stockholders of record on Monday, September 23rd were given a dividend of $0.0032 per share. The ex-dividend date was Friday, September 20th. This represents a dividend yield of 0.1%.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Bond

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.